{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["D'Cruz OJ"],"pubmed_abstract":["Background
Overexpression of the cytokine - transforming growth factor-beta 2 (TGF-β2) - has been implicated in the malignant progression of pancreatic cancer (PAC). OT-101 (trabedersen) is an antisense oligodeoxynucleotide designed to target the human TGF-β2 mRNA. In a Phase I/II study, OT-101 treatment with subsequent chemotherapy was characterized by outstanding overall survival (OS) in patients with PAC.Objective
This study sought to identify 1) co-regulated sets of cyto-/chemokines; 2) potential mechanisms that link TGF-β receptor type 2 receptor inhibition that may result in the induction of a cytokine storm; and 3) predictive biomarkers for OS outcome in OT-101-treated patients with PAC.Materials and methods
Plasma levels of 31 cyto-/chemokines were tracked o"],"journal":["OncoTargets and therapy"],"pagination":["2779-2796"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5957068"],"repository":["biostudies-literature"],"pubmed_title":["Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer."],"pmcid":["PMC5957068"],"pubmed_authors":["Ng K","D'Cruz OJ","Qazi S","Trieu V","Hwang L"],"additional_accession":[]},"is_claimable":false,"name":"Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer.","description":"Background
Overexpression of the cytokine - transforming growth factor-beta 2 (TGF-β2) - has been implicated in the malignant progression of pancreatic cancer (PAC). OT-101 (trabedersen) is an antisense oligodeoxynucleotide designed to target the human TGF-β2 mRNA. In a Phase I/II study, OT-101 treatment with subsequent chemotherapy was characterized by outstanding overall survival (OS) in patients with PAC.Objective
This study sought to identify 1) co-regulated sets of cyto-/chemokines; 2) potential mechanisms that link TGF-β receptor type 2 receptor inhibition that may result in the induction of a cytokine storm; and 3) predictive biomarkers for OS outcome in OT-101-treated patients with PAC.Materials and methods
Plasma levels of 31 cyto-/chemokines were tracked o","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2025-04-05T00:06:26.708Z","creation":"2019-03-26T23:38:18Z"},"accession":"S-EPMC5957068","cross_references":{"pubmed":["29785126"],"doi":["10.2147/OTT.S161905"]}}